|Bid||0.000 x 0|
|Ask||0.000 x 0|
|Day's Range||69.621 - 69.701|
|52 Week Range||61.930 - 74.640|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||0.35%|
To help investors keep up with the markets, we present our ETF Scorecard. The Scorecard takes a step back and looks at how various asset classes across the globe are performing. The weekly performance is from last Friday’s open to this week’s Thursday close.
Although the S&P 500 has been on a tear this year, and hit another new high yesterday, Societe Generale’s Alain Bokobza and his team don’t see that streak continuing, projecting a 2,450 close this year and 2,500 for year-end 2018. More detail from his note: Clear impact of Treasury yield on US sector performance, less obvious for US dollar: A bivariate analysis (versus the dollar and the level of rates using quarterly data from 2007 onwards) looks less compelling graphically. In materials, for example, the negative sensitivity to the dollar index is clearly visible, but it seems to be trumped by the sensitivity to higher yields, leading to a predominant outperformance in the upper right quadrant.
Now that we have a (temporary) solution to the debt ceiling debate, JPMorgan's Dubravko Lakos-Bujas and his team believe that tax reform will become the leading political cause. While we don't know the details yet, Lakos-Bujas writes that key items will likely include lowering the statutory corporate tax rate, expensing of capex and/or extension of bonus depreciation, interest expense deductibility, cash repatriation, and adoption of a territorial tax system. More from his note: Sector Implications ― as a general rule, the tax reform would benefit Domestic companies with a high effective tax rate compared to US Multinationals with an already low effective tax rate.
HSBC's Ben Laidler and Daniel Grosvenor have an update about their firm's equity strategy, writing that it recently introduced a defensive tilt to its global strategy portfolio, and increased its allocation the Telecoms sector. Year-to-date, telecom has lagged the general market, but Laidler recently upgraded it to Overweight from Neutral.
With August winding toward a close, CFRA's Sam Stovall writes that the S&P Composite 1500 appears to be on track with historical moves, down some 1.3% for the month. By contrast, food retailers, packaged goods, and advertising were the laggards, falling 3.1%, 3.5%, and 3.7%, respectively.
CFRA's Sam Stovall takes a look at how sectors have been behaving of late, writing that leaders have fallen behind. Last week, the S&P 500 fell 0.7%, and its mid- and small-cap counterparts were also lower. Nine of 11 sectors ended in the red, with the biggest losers being energy, consumer discretionary and telecom (only utilities and materials were higher for the week).
Telecom, biotech and retail ETFs outperformed early Thursday as the market kicked off June with narrow gains.
XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTLB.TA) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company developing treatments for autoimmune diseases, today announced that Mr. Alex Rabinovich has been appointed as a member of the Company's board of directors. Mr. Rabinovich is a leading investor in XTL and holds over 20% of its shares. Mr. Rabinovich will replace Mr. David Bassa, who has resigned from his position as a director of the Company, after serving as a director for seven years.
RAANANA, Israel, April 5, 2017 /PRNewswire/ -- Additional data shows a statistically significant effect in the gene expression of two additional genes that have a role in the pathogenesis of Sj ö gren ...
XTL Biopharmaceuticals Ltd. (XTLB) (XTLB.TA) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company developing treatments for autoimmune diseases, today announced that it has closed its private offering of securities for proceeds of $2.8 million. In connection with the offering, announced previously on March 7, 2017, the Company issued and sold 1,400,000 American Depository Shares (ADSs) at a purchase price of $2.00 per ADS. The Company has agreed to hold a shareholder meeting to increase its authorized ordinary shares to allow for the full exercise of the warrants (the "Authorized Capital Increase").
As previously disclosed on November 14, 2017, XTL received a letter from Nasdaq notifying the Company that it was not in compliance with Nasdaq's Listing Rule 5450(a)(1) because the minimum bid price of the Company's American Depositary Shares ("ADSs") had closed below US $1.00 per share for 30 consecutive business days. On February 28, 2017, XTL received notification from Nasdaq that the closing price of the Company's America Depository Share has been at $1.00 per share or greater for the last 10 consecutive business days from February 10 through 24, 2017.
RAANANA, Israel, February 13, 2017 /PRNewswire/ -- Dr. Robert I. Fox and Professor Simon Bowman are world-renowned rheumatologists and experts in Sjogren's syndrome XTL Biopharmaceuticals ...
What stocks should you expect to find in a European ETF? How about a homebuilder ETF? While these questions should not be hard to answer, what’s inside an ETF might surprise you and your clients. CFRA’s ETF research is based in part on the belief that an ETF is a basket of securities. So rather than judging an ETF using a rearview mirror approach, which can result in whiplash, we review the underlying holdings. The constituents of similar-sounding ETFs will be distinct, which impacts performance.
XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTLB.TA) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company developing treatments for autoimmune diseases, today announced the Company has authorized The Bank of New York Mellon, as depository ("BNY Mellon"), to effect on February 10, 2017 a change in the ratio from one (1) Depositary Share ("DS") representing twenty (20) ordinary shares to a new ratio of one (1) DS representing one hundred (100) ordinary shares. For the Company's DS holders, this ratio change will have the same effect as a reverse split on the XTL DSs on the basis of one (1) new DS for every five (5) old DSs held.
XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTLB.TA) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company developing its lead product for the treatment of lupus and other autoimmune diseases, today announced the Company's Chief Executive Officer, Josh Levine, will present at Biotech Showcase on Wednesday, January 9-11, 2017 at 3:30 pm PT in San Francisco. XTL's presentation will include an overview and the latest updates on the Company's lead compound, hCDR1, in development for the treatment of Systemic Lupus Erythematosus (SLE) and other autoimmune diseases.
XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTLB.TA) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company developing its lead product for the treatment of autoimmune diseases, today announced that it received a notice from The NASDAQ Stock Market ("NASDAQ") that the Company is not in compliance with NASDAQ's Listing Rule 5450(a)(1) because the minimum bid price of the Company's American Depositary Shares ("ADSs") has closed below US$1.00 per share for 30 consecutive business days. The notification of noncompliance has no immediate effect on the listing or trading of the Company's ADSs on The Nasdaq Capital Market.